Moreover, NCL expression was significantly increased during glial tumor progression, ranging from 32% of NCL+ cells in WHO grade I glioma to 57% in glioma grade IV (GBM) (Figure 2E). Here, NUCLEOLIN is linked to central nervous system cancer.